Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352252 | 0.87 | GAA (0.50) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL26082900 | 0.86 | MAOB (0.36) | GAAKDM4EKMT2AMAOBHTT | |
| SCHEMBL1933227 | 0.86 | MAOB (0.48) | GAAKDM4EKMT2AMAOBHTT | |
| SCHEMBL4900433 | 0.84 | GAA (0.48) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL26083148 | 0.83 | KDM4E (0.38) | GAAKDM4EKMT2AMAPK8 | |
| SCHEMBL316348 | 0.82 | SMN1; SMN2 (0.48) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL26415573 | 0.82 | GAA (0.47) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL2302254 | 0.82 | GAA (0.50) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL1463814 | 0.82 | GAA (0.47) | GAAKDM4EKMT2AMAOBMAPK8 | |
| SCHEMBL12568166 | 0.82 | GAA (0.47) | GAAKDM4EKMT2AMAOBMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022251679-A1 | NITROXIDE RADICALS FOR USE AS ANTIVIRAL TREATMENT FOR CORONAVIRUS INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-12-01 | — | — | WO | claimed |
| US-10245256-B2 | Nitroxides for use in treating or preventing diabetes and obesity | MITOS PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | claimed |
| EP-2755989-B1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2018-01-31 | — | — | EP | claimed |
| US-20170095459-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | Knobbe, Martens, Olson & Bear, LLP | 2017-04-06 | — | — | US | claimed |
| US-9522144-B2 | Nitroxides for use in treating or preventing diabetes and obesity | MITOS PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | claimed |
| US-9522143-B2 | Nitroxides for use in treating or preventing diabetes and obesity | MITOS PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | claimed |
| US-20160015699-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | Knobbe, Martens, Olson & Bear, LLP | 2016-01-21 | — | — | US | claimed |
| US-20150359782-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | Knobbe, Martens, Olson & Bear, LLP | 2015-12-17 | — | — | US | claimed |
| US-9101619-B2 | Nitroxides for use in treating or preventing diabetes and obesity | MITOS PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | claimed |
| EP-2755989-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | Stora Enso Oyj (FI) | 2014-07-23 | — | — | EP | claimed |
| WO-2013038316-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2013-03-21 | — | — | WO | claimed |
| US-12603319-B2 | Self-charging electrochemical cells | WATTRII, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12583948-B2 | Photohardenable compositions, methods, and a stabilizer | QUADRATIC 3D, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250382461-A1 | POLYROTAXANE COMPRISING CYCLIC MOLECULE WITH ALDEHYDE GROUP ADDUCT, METHOD FOR PRODUCING SAID POLYROTAXANE, STRETCHABLE BIOMATERIAL, AND METHOD FOR PRODUCING SAID BIOMATERIAL | KOKEN CO., LTD. (JP) | 2025-12-18 | — | — | US | disclosed |
| US-12461443-B2 | Photoresist resin, method for producing photoresist resin, photoresist resin composition, and method for forming pattern | DAICEL CORPORATION (JP) | 2025-11-04 | — | — | US | disclosed |
| WO-2006105354-A1 | SELECTIVE OXIDATION OF TRITERPENES EMPLOYING TEMPO | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006105357-A2 | ELECTROCHEMICAL METHOD FOR THE PRODUCTION OF BETULIN ALDEHYDE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20060110784-A1 | Site-specific labeling of proteins for NMR studies | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006036779-A2 | SITE-SPECIFIC LABELING OF PROTEINS FOR NMR STUDIES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2005003759-A1 | A METHOD FOR ANALYSIS OF A BEVERAGE | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359782-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | TXNRD2, TXN2, TET1 | GAA 2772/4885KDM4E 248/4885KMT2A 754/4885 |
| US-10245256-B2 | Nitroxides for use in treating or preventing diabetes and obesity | TXNRD2, TXN2, TET1 | GAA 2772/4885KDM4E 248/4885KMT2A 754/4885 |
| US-12583948-B2 | Photohardenable compositions, methods, and a stabilizer | NOX4, LCP1, TERB1 | GAA 4533/4885KDM4E 435/4885KMT2A 1118/4885 |
| US-20170095459-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | TXNRD2, TXN2, TET1 | GAA 2772/4885KDM4E 248/4885KMT2A 754/4885 |
| US-12603319-B2 | Self-charging electrochemical cells | SLC9A1, SLC9A2, SLC8A1 | GAA 1520/4885KDM4E 1436/4885KMT2A 1557/4885 |
| US-20160015699-A1 | NITROXIDES FOR USE IN TREATING OR PREVENTING DIABETES AND OBESITY | TXNRD2, TXN2, TET1 | GAA 2772/4885KDM4E 248/4885KMT2A 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.